

## **Avagenesis and Avapecia Announce Global Collaboration Agreement**

**February 5, 2016 – Calgary Alberta and Richmond, British Columbia:** Avagenesis Corp. (TSXV: VVA) and Avapecia Life Sciences Corp. (CSE: VVS) (“Company” or the “Companies”) are pleased to announce a Global Collaboration Agreement (“Agreement”) for Co-Distribution and Co-Marketing.

The Agreement ensures a standardized adipose stem cell therapy isolation and enrichment platform that produces a highly potent regenerative biopharmaceutical stem cell product at the point-of-care for a multitude of indications and conditions that have significant potential for use in stem cell therapies.

The combined synergies will allow focused expansion of global translational medical research with leading researchers and clinicians, the leverage of intellectual property and FDA regulatory registrations, ISO 90001 and ISO 13485 manufacturing capabilities, and business development and marketing teams of both Companies.

The Companies will collaborate to identify sales opportunities, warranty, maintenance and customer support relevant to their deployed systems in their relevant controlled medical indications. The resulting cash flow streams from these activities will be accounted for and allocated to the respective Company that holds the intellectual property for such medical indication, condition and market that the cash flow is derived from.

“With this Agreement, there is now a single unified standardized isolation and enrichment platform for stem cell therapy that will enable rapid expansion of translational medical research, standardized global multi-centre clinical trials, and a new wave of breakthroughs in regenerative medicine”, stated Norman Tsui, CEO of Avagenesis Corp.

Dr. Peter Neweduk, CEO of Avapecia added, “This system is simply the best, most practical and cost effective platform in the world for adipose stem cell researchers to adopt.”

Avagenesis and Avapecia are related parties by virtue of having common controlling shareholders and certain Directors and Officers.

### **About Avagenesis Corp.**

Avagenesis is a biotechnology company engaged in the commercialization of licensed cell isolation medical technologies for use in regenerative medical aesthetics, wound management and non-healing wounds, cardiovascular and heart diseases, peripheral arterial disease, critical limb ischemia or diabetic leg, hepatic disease and kidney disease.

### **About Avapecia Life Sciences Corp.**

Avapecia is a biotechnology company engaged in the research, development and commercialization of regenerative stem cell technologies and therapy solutions for use in urogynaecology, urology, hair loss (prevention, maintenance, and regeneration), gastrointestinal diseases, respiratory medicine, neurodegenerative diseases, ophthalmology, spinal cord injuries and certain autoimmune diseases. Avapecia’s bioprocessing platform provides third party validated standardized isolation of safe, high quality, viable, and potent stem cells from a patient’s own fat, or adipose tissue, for use in current and future cell therapy applications.

***Neither the Exchange nor its regulation services provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this press release.***

### **Cautionary Statements**

*Certain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could", "intend", "expect", "believe", "will", "projected", "likely", "estimated" and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on current belief or assumptions as to the outcome and timing of such future events. Actual future results and developments may differ materially from those contemplated by these statements depending on, among other things, the risk that the Company may not successfully transition to a clinical stage company and successfully execute its development and commercialization activities. Various assumptions or factors are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking information. Those assumptions and factors are based on information currently available to the Company. Readers are cautioned that the above list of risk factors is not exhaustive. The forward-looking information contained in this press release is made as of the date hereof and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties and assumptions contained herein, investors should not place undue reliance on forward-looking information. The foregoing statements expressly qualify any forward-looking information contained herein.*

### **Further Information**

For further information, please contact:

Avagenesis Corp. or Avapecia Life Sciences Corp.  
Alan Tam, CPA, CA  
Chief Financial Officer  
Telephone: (604) 227-9287